Saturday 17 October 2026
Export AQST’s income statement to Excel — free account
Aquestive Therapeutics, Inc.
AQST Healthcare Drug Manufacturers Specialty & Generic
Aquestive Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, down 22.6% from fiscal 2024. In the quarter to June 2026, revenue grew 38.2%, EPS fell 28.6%, free cash flow fell 20.4% and total debt rose 59.1%, each against the same quarter a year earlier.
3.78
0.28
−6.90%
Follow AQST
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
14.24 | 15.51 | 10.12 | 9.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(48.87) | (81.56) | (34.37) | (55.08) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
11.96 | 13.40 | 8.42 | 8.73 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.29) | (11.39) | (9.65) | (10.41) | |
EV/FCF |
(10.19) | (11.27) | (9.55) | (10.28) | |
Quick Ratio |
5.51 | 2.92 | 3.70 | 6.54 | |
Current Ratio |
5.93 | 3.14 | 4.10 | 7.19 | |
Net Debt/EBITDA |
11.54 | 3.61 | 47.44 | 7.57 | |
Debt/Assets |
18.31% | 17.15% | 17.78% | 38.34% | |
Debt/Equity |
(7.29) | (0.82) | (0.74) | (0.90) | |
Asset Turnover |
0.32 | 0.34 | 0.41 | 0.48 | |
Operating CF/Net income |
0.82 | 0.27 | 1.84 | 0.41 | |
Capex/Depreciation |
(0.08) | (0.03) | (0.02) | (0.11) | |
Interest Coverage |
(2.69) | (6.75) | (1.07) | (2.14) | |
Research and Development Expense of Revenue |
35.37% | 24.56% | 29.10% | 28.67% | |
Selling, General and Administrative Expense of Revenue |
119.08% | 252.19% | 75.99% | 101.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
21.68% | 10.57% | 16.05% | 20.95% | |
Graham Net Nets |
(0.03) | (0.06) | (0.09) | (0.13) | |
Graham Number |
0.77 | 2.35 | 1.95 | 2.57 | |
Earnings Yield |
(12.70%) | (12.07%) | (14.70%) | (15.63%) | |
Free Cash Flow Yield |
(8.24%) | (7.67%) | (8.71%) | (8.84%) | |
Revenue per Share |
0.12 | 0.12 | 0.12 | 0.11 | |
Operating CF per Share |
(0.11) | (0.08) | (0.12) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.08) | (0.12) | (0.08) | |
Cash per Share |
1.17 | 1.13 | 0.90 | 0.79 | |
Shareholders Equity per Share |
(0.04) | (0.31) | (0.28) | (0.45) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.04) | (0.31) | (0.28) | (0.45) | |
Free Cash Flow |
(12.88) | (8.55) | (14.86) | (9.65) | |
Working Capital |
126.10 | 101.66 | 98.43 | 102.02 | |
Capital Expenditures |
(0.23) | (0.08) | (0.05) | (0.21) | |
Net Current Asset Value |
(15.99) | (44.82) | (45.00) | (70.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.74 | 12.55 | 8.66 | 10.60 | |
Average Payables |
9.22 | 20.07 | 12.08 | 10.46 | |
Average Inventory |
7.45 | 6.11 | 7.63 | 7.75 | |
Average Assets |
136.76 | 130.92 | 121.68 | 112.90 | |
Average Common Equity |
(24.76) | (46.91) | (47.49) | (64.59) |
Columns are period end dates